Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

NCT06770582 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

NIH

Sponsor class

Conditions

Non-Muscle Invasive Bladder Urothelial Carcinoma
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage I Bladder Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cisplatin
PROCEDURE: Computed Tomography
DRUG: Fluorouracil
DRUG: Gemcitabine
PROCEDURE: Magnetic Resonance Imaging
DRUG: Mitomycin
BIOLOGICAL: Pembrolizumab
OTHER: Questionnaire Administration
RADIATION: Radiation Therapy

Sponsor

National Cancer Institute (NCI)